Brief: Matinas Biopharma Provides Positive Outcomes Update On The MAT2203 Compassionate/Expanded Use Access Program
26/02/2024 13:18
Feb 26 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA PROVIDES POSITIVE OUTCOMES UPDATE ON THE
MAT2203 COMPASSIONATE/EXPANDED USE ACCESS PROGRAM, INCLUDING
MULTIPLE PATIENTS WITH COMPLETE CLINICAL RESOLUTION
* MATINAS BIOPHARMA PROVIDES POSITIVE OUTCOMES UPDATE ON THE
MAT2203 COMPASSIONATE/EXPANDED USE ACCESS PROGRAM, INCLUDING
MULTIPLE PATIENTS WITH COMPLETE CLINICAL RESOLUTION
* MATINAS BIOPHARMA HOLDINGS INC - A TOTAL OF 19 PATIENTS
WITH
SERIOUS/LIFE-THREATENING INVASIVE FUNGAL INFECTIONS HAVE BEEN
ENROLLED
* MATINAS BIOPHARMA HOLDINGS INC - TREATMENT WITH MAT2203
WAS WELL
TOLERATED AND LED TO FAVORABLE CLINICAL AND RADIOLOGICAL
RESPONSE
Source text for Eikon: ID:nGNX5chM3f
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing